Pacific Biosciences of California, Inc.
http://www.pacb.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pacific Biosciences of California, Inc.
Stock Watch: Biogen, Blood In The Water
When almost everything that could go wrong has gone wrong at a company, the proposition of it turning acquirer may meet with some resistance from its proposed targets and their investors.
Mysterious Perlmutter-Helmed Start-Up Eikon Raises $517.8m
Eikon launched in 2021 with $148m in series A venture capital and former Merck R&D head Roger Perlmutter as its CEO, but even with half a billion dollars in fresh cash, the firm has not revealed its therapeutic focus.
Dealmaking Quarterly Statistics, Q3 2021
In the third quarter of 2021, medical device company M&A values reached $7.1bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $6.7bn.
PacBio Agrees To Pay $800M For Omniome To Add Complementary Short-Read Sequencing Platform
Pacific Biosciences has agreed to pay $600m upfront in cash and stock and up $200m in additional milestone payments to acquire Omniome. PacBio also announced a new private placement of common stock to raise $300m.
Company Information
- Industry
- Research, Analytical Equipment & Supplies
-
Biotechnology
- Nanotechnology, Chips, etc.
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- PacBio